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Abstract
Background: Large studies on severe imported malaria in non-endemic industrialized countries are lacking. We sought to
describe the clinical spectrum of severe imported malaria in French adults and to identify risk factors for mortality at
admission to the intensive care unit.
Methodology and Principal Findings: Retrospective review of severe Plasmodium falciparum malaria episodes according to
the 2000 World Health Organization definition and requiring admission to the intensive care unit. Data were collected from
medical charts using standardised case-report forms, in 45 French intensive care units in 2000–2006. Risk factors for in-
hospital mortality were identified by univariate and multivariate analyses. Data from 400 adults admitted to the intensive
care unit were analysed, representing the largest series of severe imported malaria to date. Median age was 45 years; 60% of
patients were white, 96% acquired the disease in sub-Saharan Africa, and 65% had not taken antimalarial chemoprophylaxis.
Curative quinine treatment was used in 97% of patients. Intensive care unit mortality was 10.5% (42 deaths). By multivariate
analysis, three variables at intensive care unit admission were independently associated with hospital death: older age (per
10-year increment, odds ratio [OR], 1.72; 95% confidence interval [95%CI], 1.28–2.32; P=0.0004), Glasgow Coma Scale score
(per 1-point decrease, OR, 1.32; 95%CI, 1.20–1.45; P,0.0001), and higher parasitemia (per 5% increment, OR, 1.41; 95%CI,
1.22–1.62; P,0.0001).
Conclusions and Significance: In a large population of adults treated in a non-endemic industrialized country, severe
malaria still carried a high mortality rate. Our data, including predictors of death, can probably be generalized to other non-
endemic countries where high-quality healthcare is available.
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Introduction
Plasmodium falciparum malaria remains a major public health
problem in endemic areas, with more than 1,000,000 deaths each
year. About 12,000 cases of imported malaria are reported
annually in Europe [1] and about 1300 in the United States [2].
Among non-endemic countries, France has the highest number of
cases, about 5000 per year, of which 20 to 30 are fatal [3]; the
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13236second highest number is found in the United Kingdom, where
the incidence is rising [4].
Severe imported malaria still carries a high mortality rate,
which is estimated at 10% to 15%, although large studies are
lacking [3]. One of the objectives of the World Health
Organization (WHO) program for malaria control in Europe is
to identify risk factors for death that can be used to optimize
treatment decisions. In 2003, we reported several risk factors
identified in 188 patients admitted to a single French intensive care
unit (ICU) in 1988–1999 [5]. Although this study was the largest
on managing severe malaria in a non-endemic industrialized
country, it was conducted in a single center, over a long period,
and used the 1990 WHO definition of severe malaria [6]. The
WHO issued a new definition in 2000 [7]. Moreover, new
treatment strategies for severe sepsis have been introduced over
the last decade.
The objectives of this study were to gather multicenter data
about severe imported malaria managed in the ICU in recent
years, and to identify risk factors for mortality present at ICU
admission.
Methods
Ethics Statement
Our study was approved by the Ethics Committee of the French
Society for Critical Care Medicine (approval #07-211). Due to the
retrospective design of the study, we did not obtain informed
consent from the included patients. Nevertheless, all the data
collected retrospectively were anonymized in a standardized case-
report form and in the database.
Study sites and population
The study was performed in the 45 adult ICUs in France that
constitute the SIMA Study Group of 30 civilian university
hospitals, three military teaching hospitals, and 12 regional
nonteaching hospitals. Consecutive adults admitted to the 45
ICUs with a diagnosis of severe falciparum malaria between
January 2000 and October 2006 were included and data were
collected retrospectively (in 2006–2007) from the medical charts
using standardized case-report forms.
Definitions
According to the 2000 WHO definition [7], severe imported
malaria was defined in this study as the combination of, (i) asexual
P. falciparum forms in blood or a positive result of the P. falciparum
histidine-rich protein 2 antigen-based rapid test, and (ii) one or
more severity criteria (Table 1) at admission or within the first 2
days, and (iii) requirement of ICU admission (at the discretion of
the ICU physicians). The 2000 WHO definition of severe malaria
[7] was modified in part according to the SEAQUAMAT group
[8]. More specifically, respiratory distress criteria were defined as
stated in Table 1. Moreover, and to better characterize lung
injury, we also defined respiratory failure as follows: in
spontaneously breathing patients, PaO2 ,60 mmHg on room
air or need for supplemental oxygen and/or respiratory rate .32/
min; and in patients receiving ventilatory assistance, PaO2/FiO2
ratio ,200 mmHg.
Nonimmune patients were defined as Caucasians who traveled
occasionally to endemic areas [5].
Community-acquired co-infection was defined as any infection
diagnosed within the first 2 days after hospital admission.
Infections occurring later were considered nosocomial. Acute lung
injury (ALI) and acute respiratory distress syndrome (ARDS) were
defined according to Bernard et al. [9].
Management
Treatment, particularly the management of organ dysfunctions
(including levels for blood products transfusions), was at the
discretion of the ICU physicians. During the study period, recent
and detailed French guidelines for the management of severe
Table 1. Clinical and biological criteria for severe malaria according to the 2000 World Health Organization definition with
modifications (see * and {).
Clinical criteria
Impaired consciousness: Glasgow Coma Scale score ,11*
Respiratory distress: requirement for noninvasive and/or endotracheal mechanical ventilation or spontaneous breathing with PaO2 ,60 mm Hg (if FiO2 $0.21) {, and/or
respiratory rate .32/min*
Multiple convulsions
Circulatory collapse: systolic blood pressure ,80 mm Hg despite adequate volume repletion
Abnormal bleeding
Jaundice: clinical jaundice or bilirubin .50 mmol/L
Macroscopic hemoglobinuria: if unequivocally related to acute malaria (patients with blackwater fever were not included)
Laboratory criteria
Severe anemia: hemoglobin ,5 g/dL
Hypoglycemia: blood glucose ,2.2 mmol/L
Acidemia (pH,7.35) or acidosis (serum bicarbonate ,15 mmol/L)
Hyperlactatemia: arterial lactate .5 mmol/L
Hyperparasitemia $4%
Renal impairment: serum creatinine .265 mmol/L or blood urea nitrogen .17 mmol/L*
*Coma scale criteria of 11 instead of 9; respiratory rate .32/minute and blood urea nitrogen . 17 mmol/L are modifications according to the SEAQUAMAT group [8].
{The requirement for noninvasive and/or endotracheal mechanical ventilation or spontaneous breathing with PaO2 ,60 mm Hg (if FiO2 $0.21) was used specifically for
this study.
doi:10.1371/journal.pone.0013236.t001
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recommended a quinine loading dose but did not recommend
exchange transfusion.
Blood culture for microbiology and chest X-ray were performed
routinely at ICU admission. Neuroimaging, electroencephalogram
and hemodynamic investigations were performed if deemed
necessary by the attending physician.
Data collection
We recorded demographic data; previous medical history;
country of malaria acquisition; chemoprophylaxis; clinical,
laboratory, and imaging findings; and treatments and vital status
at ICU and hospital discharge. Severity at ICU admission was
assessed by computing the Glasgow Coma Scale (GCS) score [11],
Simplified Acute Physiology Score II (SAPS II) [12], and
Sequential Organ Failure Assessment (SOFA) score [13]. In each
ICU, one intensivist completed a standardized case-report form
for each patient. All case-report forms were reviewed by one of us
(FB) for identification and resolution of inconsistencies.
Statistical analysis
A descriptive analysis was performed on the overall sample.
Categorical variables were described with numbers and percent-
ages and continuous variables with mean and SD, or with median
and interquartile range [IQR] for nonnormally distributed
variables. Survivors and nonsurvivors were compared using the
chi-square test for categorical variables and the Student’s t-test or
Wilcoxon rank-sum test, as appropriate, for continuous variables.
To identify risk factors for mortality, we constructed logistic
regression models using a combination of multiple imputations
and bootstrapping to select prognostic variables and to handle
missing data [14]. Potential risk factors were as follows (*worst
value during the 24 hours after ICU admission): sex, ethnic origin,
co-morbidities, pulmonary failure*, shock*, age, time from
symptom onset to ICU admission, GCS score*, plasma bicarbon-
ate*, hemoglobin*, leukocytes*, platelets*, prothrombin time*,
plasma creatinine*, highest blood glucose*, lowest blood glucose*,
total serum bilirubin*, ALAT*, and parasitemia*. From the initial
data set, we constructed 1000 bootstrap data sets and performed
automatic stepwise logistic regression in each, selecting variables
associated with mortality with P,20% by univariate analysis.
Then, variables were selected for the second step if they were
associated with mortality with P values ,20% in at least 20% of
the 1000 models. We implemented multiple imputation of missing
data, which yielded five data sets. We then constructed 1000
bootstrap data sets for each imputed data set (i.e., 5000 data sets)
and performed automatic stepwise logistic regression in each.
Variables present in at least 60% of the 5000 models were selected
for the final model. In the last step, we used the mean of the
coefficient estimations obtained in each of the five imputed data
sets. SAS 9.1 software (SAS Inc, Cary, NC) was used for all
statistical analyses.
Results
During the study period, 400 patients admitted to the ICU for
severe falciparum malaria, were included. The median number of
patients per center was 7 (IQR, 5–10; range, 2 to 35).
General characteristics of the 400 patients
These characteristics are reported according to survival status in
Table 2. Falciparum malaria was acquired in sub-Saharan Africa
in 95.5% of the 366 patients for whom this information was
available. Median stay duration in the endemic area was 1.0
month (IQR, 0.5–2.0). Of the 34.7% of patients who reported
taking anti-malarial chemoprophylaxis, only 45.5% reported good
adherence. Conditions associated with immune deficiency were
noted in 7.3% of patients. One or more co-morbidities were
present in 14.3% of patients. Five patients were pregnant.
Baseline patient characteristics and antimalarial therapy
at ICU admission
The main clinical and laboratory characteristics and the pattern
of WHO severity criteria during the first 24 hours in the ICU in
survivors and nonsurvivors are reported in Tables 3 and 4,
respectively.
Overall, median parasitemia at ICU admission was 7.0% (IQR,
2.7–15.0%). P. falciparum was identified in thin blood films in
84.7% of patients and/or in thick blood films in 50.7% and/or by
antigen detection in 11.5%.
Intravenous quinine was used in 391 (97.8%) patients and other
antimalarials in 9 patients. A quinine loading dose was used in 244
(61%) patients. The mean loading dose was 10726359 mg,
consistent with the mean body weight (72.7614.5 kg) and French
Table 2. General characteristics of the 400 patients admitted to the intensive care unit with severe malaria by survival status.
Parameter Survivors n=358 Nonsurvivors n=42 P value*
Mean age (6SD), years 42.8615.0 55.6614.2 ,0.0001
Male, % 68.3 83.3 0.04
White, % 57.7 79.5 0.01
Black, % 36.0 12.8
Other, % 6.3 7.7
Previous malaria episodes, % 23.4 17.1 0.36
Antimalarial chemoprophylaxis, % 34.8 34.1 0.94
Nonimmune patients, % 43.8 59.5 0.05
At least one co-morbidity, % 13.1 23.8 0.06
Immune deficiency, % 7.8 2.6 0.34
Mean time from symptom onset to ICU admission (6SD), days 5.465.1 6.264.6 0.14
ICU, intensive care unit; SD, standard deviation.
*according to univariate analysis.
doi:10.1371/journal.pone.0013236.t002
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Parameter Survivors n=358 Nonsurvivors n=42 P value*
SAPS II, mean6SD 30.2615.6 70.6626.3 ,0.0001
SOFA score, mean6SD 7.763.8 15.465.2 ,0.0001
Glasgow Coma Scale score, median [IQR] 15.0 [12.0–15.0] 9.0 [3.0–14.0] ,0.0001
Respiratory failure % 13.4% 45.2% ,0.0001
Highest temperature in uC, mean6SD 39.061.1 38.761.1 0.08
Arterial pH, mean6SD 7.4160.1 7.1960.2 ,0.0001
Serum bicarbonates in mmol/L, mean6SD 21.76 4.7 15.767.2 ,0.0001
Arterial lactate in mmol/L, median [IQR] 2.4 [1.6–4.0] 8.4 [4.5–16.0] ,0.0001
Hemoglobin in g/dL, mean6SD 10.362.6 9.262.9 0.01
WBC?10
3/mm
3, median [IQR] 6.4 [4.7–9.6] 9.7 [5.9–17.9] 0.004
Platelet count?10
3/mm
3, median [IQR] 35.0 [19.0–57.0] 19.0 [13.0–29.0] ,0.0001
Plasma prothrombin time in %, mean6SD 72.6616.8 53.4626.8 ,0.0001
Serum creatinine inmmol/L, median [IQR] 117.0 [87.0–228.0] 203.0 [156.0–302.0] ,0.0001
Lowest serum glucose in mmol/L, mean6SD 5.462.1 4.762.4 0.03
Highest serum glucose in mmol/L, mean6SD 9.664.5 12.365.9 0.0002
Total bilirubin in mmol/L, median [IQR] 51.5 [28.0–82.5] 99.0 [47.0–181.0] ,0.0001
Parasitemia first day in %, median [IQR] 6.0 [2.0–14.0] 17.0 [7.5–30.0] ,0.0001
Serum sodium in mmol/L, mean6SD 131.965.8 132.469.2 0.90
Serum potassium in mmol/L, mean6SD 3.860.6 4.161.1 0.09
Serum ALAT in IU, median [IQR] 58.0 [35.0–108.0] 104.5 [68.0–261.0] ,0.0001
Serum lactate dehydrogenase in IU, median [IQR] 966.0 [600.0– 1428.0] 2239.5 [1121.0–4128.0] ,0.0001
Serum C-reactive protein in mg/L, mean6SD 165.2686.8 198.8693.7 0.06
ICU, intensive care unit; SD, standard deviation; IQR, interquartile range; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment; WBC,
white blood cell count; ALAT, alanine aminotransferase; IU, international units.
*according to univariate analysis.
doi:10.1371/journal.pone.0013236.t003
Table 4. Severity criteria in the 400 patients at intensive care unit admission, according to outcome.
Severity criteria Survivors n=358 Nonsurvivors n=42 P value*
Impaired consciousness, n (%) 77 (21.5) 26 (62.0) ,0.0001
Respiratory distress, n (%) 72 (20.1) 29 (69.1) ,0.0001
Multiple convulsions, n (%) 22 (6.2) 5 (11.9) 0.1849
Shock, n (%) 69 (19.3) 26 (61.9) ,0.0001
Abnormal bleeding, n (%) 7 (2.0) 3 (7.1) 0.0766
Jaundice, n (%) 178 (49.7) 30 (71.4) 0.0077
Hemoglobinuria, n (%) 20 (5.6) 2 (4.8) 1.0000
Severe anemia, n (%) 10 (2.8) 4 (9.5) 0.0453
Hypoglycemia, n (%) 5 (1.4) 8 (19.1) ,0.0001
Acidosis, n (%) 43 (12.0) 27 (64.3) ,0.0001
Hyperlactatemia, n (%) 37 (10.3) 26 (61.9) ,0.0001
Parasitemia . 4%, n (%) 223 (62.3) 34 (81.0) 0.0170
Renal impairment, n (%) 111 (31.0) 26 (61.9) ,0.0001
Mean number of severity criteria during the first 24 hours in the ICU (6 SD) 2.461.6 5.962.4 ,0.0001
WHO, World Health Organization; ICU, intensive care unit.
*according to univariate analysis.
doi:10.1371/journal.pone.0013236.t004
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patients who received no loading dose, 9 did not receive quinine,
90 had received curative antimalarial treatment within hours
before ICU admission, and 57 were not considered to require a
loading dose (less severe form of malaria according to the
physician in charge). An antibiotic was added in 36 patients. No
patient underwent exchange transfusion.
Complications of malaria and management
In 97 (24.3%) patients, at least one WHO defining criterion that
was absent during the first 24 hours developed over the next
48 hours: impaired consciousness (n=20), respiratory distress
(n=45), multiple convulsions (n=6), shock (n=26), abnormal
bleeding (n=6), jaundice (n=12), hemoglobinuria (n=2), severe
anemia (n=6), hypoglycemia (n=5), acidosis (n=10), hyperlacta-
temia (n=7), hyperparasitemia (n=4), and renal function
impairment (n=23).
Consciousness was impaired in 123 patients (103 at admission),
for a mean duration of 2 days (IQR, 1–6; range, 1–67).
Convulsions occurred in 33 patients, of whom 21 needed
anticonvulsant therapy. Focal neurological abnormalities were
present in 22 patients. Cerebral computed tomography (CT) and/
or magnetic resonance imaging (MRI) were performed in 76 and
13 patients, respectively, and the findings were abnormal in 23
patients. At ICU discharge, 24 patients had at least one residual
neurological abnormality: mental status abnormalities (n=12),
persistent focal deficits (n=8), critical-illness polyneuropathy
(n=6), epilepsy (n=2), and other abnormalities (n=7).
On the first day, fluid resuscitation was given to 247 (61.7%)
patients, including 213 (213/358, 59.5%) survivors and 34 (34/42,
81.0%) nonsurvivors (P=0.0068). Throughout the ICU stay, 109
patients received catecholamines (norepinephrine, n=81; and/or
epinephrine, n=26; and/or dopamine; n=27; and/or dobuta-
mine, n=25), including 71 (71/358, 19.8%) survivors and 38 (38/
42, 90.5%) nonsurvivors (P,0.0001).Low-dose steroids were used
in 43 patients and activated protein C in only 3 patients.
At least one co-infection was diagnosed during the ICU stay in
96 patients (24.0%), including 78 (78/358, 21.8%) survivors and
18 (18/42, 42.9%) nonsurvivors (P=0.0025). Community-ac-
quired bacterial infections were diagnosed in 30 (30/96, 31.2%)
patients including 25 (25/358, 7.0%) survivors and 5 (5/42,
11.9%) nonsurvivors (P=0.2520). In the remaining 66 (66/96,
68.8%) patients with bacterial infections, the first episode was
nosocomially acquired; 53 (53/358, 14.8%) of these patients were
among the survivors and 13 (13/42, 31.0%) among the
nonsurvivors (P=0.0076). The main co-infection sites and
microorganisms are detailed in the Table 5.
Endotracheal mechanical ventilation was required in 116 (116/
395, 29.4%) patients, for a median duration of 6 days (IQR, 3–14;
range, 1–201). In addition, 32 patients received noninvasive
ventilation, which failed in 16 patients, who then received
endotracheal mechanical ventilation. Thus, mechanical ventilation
was used in 132 patients, of whom 90 survived and 42 died.
Nonhemodynamic pulmonary edema was present in 76 (57.5%) of
the 132 ventilated patients; among them, 58 had ARDS and 18
had ALI. The 56 other patients received ventilatory assistance
essentially because of unarousable coma.
During the ICU stay, 81 patients required renal replacement
therapy (intermittent hemodialysis, n=64; and/or continuous
veno-venous hemodiafiltration, n=49).
Abnormal bleeding occurred in 23 patients. Blood transfusions
were required in 114 patients, platelets in 63, and fresh plasma in
24. Overall, 845 blood-product units were transfused (538 blood,
177 platelets, and 130 fresh plasma units).
Outcomes and factors predicting death
The overall hospital mortality rate was 10.5% (95% confidence
interval [95%CI], 7.5%–13.5%), because all 42 deaths occurred in
the ICU. The main characteristics of the nonsurvivors and causes of
death are shown in Table S1. Death occurred within the first ICU
week in 32 (76.2%) patients. Median ICU stay duration in the 42
patients who died was 3.5 days (IQR, 2–7; range, 1–198). Median
ICU and hospital stay durations in survivors were 5 days (IQR, 3–8;
range, 1–186) and 10 days (IQR, 7–17; range, 1–189), respectively.
By multivariable analysis, three variables present within
24 hours after ICU admission were significantly associated with
death in the ICU: older age, lower Glasgow Coma Scale score,
and higher parasitemia (Table 6).
Discussion
In 400 adults with severe imported malaria, ICU mortality was
10.5%. Three variables present at ICU admission independently
predicted death: older age, coma, and higher parasitemia.
Table 5. Data on the 96 first episodes of co-infection in the 400 adults with severe imported malaria.
Parameter Community-acquired infections n=30 Nosocomial infections n=66
Pneumonia
Microorganisms
(number of episodes)
13 episodes
Streptococcus pneumoniae (3), MS Staphylococcus aureus
(3), Gram+ cocci (negative culture) (1), Escherichia coli (1),
Haemophilus influenzae (1), Klebsiella pneumoniae (1),
Enterobacter cloacae (1), Acinetobacter baumannii (1),
Pseudomonas aeruginosa (1), Not documented (2)
48 episodes
MS S. aureus (11), Streptococcus sp (7), S. pneumoniae (3), MR S.
aureus (1), H. influenzae (9), E. coli (4), K. pneumoniae (1),
Enterobacter aerogenes (3), E. cloacae (2), A. baumannii (3), P.
aeruginosa (5), Bulkholderia cepacia (1), Legionella pneumophila
(1), Citrobacter koseri (1), Not documented (6)
Bacteremia
Microorganisms
(number of episodes)
10 episodes
E. coli (3), P. aeruginosa (1), Alcaligenes xylosoxidans (1),
Clostridium sp (1), K. pneumoniae (1), Salmonella typhi (1),
Campylobacter jejuni (1), Candida albicans (1)
8 episodes
E. coli (4), MS S. aureus (1), Staphylococcus epidermidis (1),
Klebsiella oxytoca (1), S. typhi (1)
Urinary tract infection
Microorganisms
(number of episodes)
3 episodes
E. coli (2), Proteus sp (1)
9 episodes
E. coli (5), K. pneumoniae (3), Enterococcus sp (2)
Other sites of infection
(number of episodes)
Abdominal infection (3), Skin and soft tissue (1) Catheter infection (3), Sinusitis (2)
MS, methicillin-susceptible; MR, methicillin-resistant.
doi:10.1371/journal.pone.0013236.t005
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imported falciparum malaria in adults managed in a nonendemic
country with high-level intensive-care facilities. It provides useful
insights on disease outcomes and variables contributing to
mortality, at least in France. These results should prove useful to
clinicians managing severe malaria patients in the ICU, as well as
to epidemiologists and public health practitioners studying
potential risk factors for mortality in severe imported malaria.
They may help to provide recommendations for intensivists,
especially in countries where imported malaria is uncommon.
Whether our results can be generalized to other nonendemic
countries deserves discussion. The few recent studies on severe
imported malaria cannot be compared directly, for multiple
reasons. Nevertheless, a number of points are shared by our study
and recent studies from the UK and US [2,4,15,16]: the majority
of severe cases are related to P. falciparum, stay duration in endemic
areas is around 20–30 days [4,16], and fewer than 15% of patients
take adequate chemoprophylaxis [2,4,15]. These common points
suggest that our results may be at least partly relevant to other
nonendemic countries having similar levels of intensive care.
Finally, our results may serve as a reference for achievable survival
rates and evaluations of complication rates in nonimmune
individuals in resource-poor settings, where the investigations
needed to characterize complications may be unavailable (e.g.,
routine high-quality chest X-ray, neuro-imaging studies, routine
blood cultures, and hemodynamic measurements).
The definition of severe falciparum malaria issued by the WHO
in 2000 is accompanied with data on the frequency and prognostic
value of the defining criteria [7]. However, few such data are
available for adults with severe imported malaria [3]. In our
cohort, neither seizure activity nor hemoglobinuria was signifi-
cantly associated with death in the univariate analysis. Among the
other criteria, bleeding, anemia, and hypoglycemia are very
uncommon in adults, and their prognostic relevance is therefore
unclear. In our univariate analysis, six WHO criteria present
within 24 hours of ICU admission were common and strongly
correlated with ICU mortality, namely, impaired consciousness,
respiratory distress, shock, metabolic acidosis, hyperlactatemia,
and renal failure. Parasitemia .4% and jaundice were the two
most common WHO criteria but were less strongly associated with
mortality. We compared the main WHO severity criteria at
admission in our 400 adults (including 182 nonimmune patients)
and in 1050 Asian patients (including 11% young children and
26% older children) from low-transmission areas [17]. Globally,
our population had (1) lower rates of coma, convulsions, acidosis,
respiratory distress, and anemia; (2) similar rates of jaundice and
renal failure; and (3) higher rates of shock and hyperparasitemia.
Nevertheless, a large number of factors can influence the
presentation, particularly access to healthcare (and more specif-
ically to high-level intensive care) and time from symptom onset to
hospital admission. Furthermore, the characteristics of the
compared populations are often noticeably different in terms of
age, proportion of pediatric patients, ethnic origin, level of anti-
malaria immunity, background health status, and living standards.
Severe imported malaria continues to carry a high mortality
rate even when high-quality healthcare is available and the
affected population is chiefly composed of healthy adults. In our
previous single-center retrospective study, mortality was 11% in
the 93 patients with severe disease [5]. Among 76 episodes of
severe adult imported malaria seen in the UK in 1991–2006, 8%
were fatal [15]. These findings are consistent with our 10.5%
mortality rate. In the two main trials of artemisinin derivatives
versus quinine in adults with severe falciparum malaria in endemic
areas, higher mortality rates of 15% versus 22%, and 13% versus
17%, respectively, were found [8,18]. Although populations in
endemic and nonendemic areas are not comparable, we believe
the lower mortality in our study than in the quinine groups of these
two trials is mainly ascribable to the availability of optimal
treatments for organ failures and to the better baseline health
status of our population.
Our multivariable analysis identified three factors present at
ICU admission and predictive of death. Older age independently
predicted death, in keeping with recent data from both endemic
and nonendemic areas [17,19]. This adverse impact of older age
should receive careful attention given the increasing numbers of
older travelers. Consciousness impairment assessed using the GCS
score on the first ICU day also independently predicted death in
our study. In our previous study, several factors, including
impaired consciousness, were associated with death by univariate
analysis, but the number of nonsurvivors was too small for a
multivariable analysis [5]. Our findings in patients with severe
imported malaria agree with the largest recent study conducted in
endemic areas, which found that the main independent predictors
of death were cerebral malaria (as assessed by the Glasgow Coma
Score) and acidosis [20]. In contrast to studies from Africa and
Asia, our study found no independent effect of acidosis at ICU
admission on the risk of death. We included serum bicarbonate
instead of arterial lactate in the multivariate analysis, because we
had missing data on lactate levels, which probably contributed to
the lack of significance of arterial lactate in the multivariate model.
The missing lactate data can be ascribed chiefly to the
retrospective study design, as arterial lactate was not measured
routinely in patients at the lower end of the severity range,
especially at the beginning of the study period. Unfortunately, base
excess was not available on our case-report form. Nevertheless,
bicarbonate and base excess, as measures of acidosis, were of
roughly similar prognostic value, as shown in a recent study [20].
The third variable independently associated with death was
parasitemia at ICU admission. The prognostic impact of
parasitemia in severe malaria patients varies with multiple factors
including geographic area, ethnicity, level of anti-malaria
immunity, and previous exposure to antimalarial agents. Further-
more, parasitemia may chiefly reflect the circulating parasite load,
which may not mirror the amount of parasites sequestered in the
microvasculature. One group showed that total-body parasite
biomass estimated from the plasma concentration of P. falciparum
histidine-rich protein 2 (HRP2) predicted death more reliably than
did parasitemia [21]. Few data are available on the prognostic
significance of parasitemia in patients with severe imported
malaria [3]. In our earlier study, median parasitemia was 18.2%
in the 10 nonsurvivors and 3.5% in the 83 survivors (P=0.02) but
the difference was not significant after adjustment [5]. According
to WHO guidelines, parasitemia .4% is sufficient to indicate
treatment for severe malaria [22]. In a recent study including 482
Table 6. Independent predictors of death at intensive care
unit admission in the 400 patients.
N OR (95%CI) P value
Age (per 10-year increment) 400 1.72 [1.28–2.32] 0.0004
Glasgow Coma Scale score
(per 1-point increment)
400 1.32 [1.20–1.45] ,0.0001
Parasitemia (per 5% increment) 400 1.41 [1.22–1.62] ,0.0001
R
2 of the model: 0.90.
OR, odds ratio; 95%CI, 95% confidence interval.
doi:10.1371/journal.pone.0013236.t006
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fatal, the odds of having severe falciparum malaria were 12 times
higher in patients with parasitemia $2% than in those with
parasitemia ,2% [15]. Further studies are needed to clarify the
relevance of both parasitemia and plasma P. falciparum HRP2 as
predictors of death in adults with severe imported malaria.
Although an earlier study showed that ethnic origin was an
independent risk factor for severe malaria [15], ethnic origin did
not independently predict death in our study. We cannot rule out
a weak association of ethnic origin with mortality in patients who
already have severe malaria, and our sample size may have been
too small to detect a statistically significant effect.
Finally, to better assess the relevance of co-infections, we
included ‘‘at least one infection’’ in the multivariable model. This
parameter was not significant, suggesting that it did not
independently predict death. In our setting, co-infections seem
associated with severity rather than independently responsible for
increased severity.
Our study has strong points compared to the main recent
studies of severe imported malaria [5,15]. The patient population
is considerably larger and comes from 45 different centers, which
increases the general validity of our findings. Furthermore, our
study covers a recent period and therefore reflects the impact of
the many recent advances in the management of severe sepsis
[23,24]. Finally, nearly all the patients received quinine therapy
and, therefore, our results were not confounded by differences in
the antimalarial drugs used. One limitation of our study is the
retrospective design. However, the database was established by
collecting information on consecutive patients using standardized
data-collection forms. To obtain an adequate recruitment rate, we
had to select adult ICUs experienced in the management of severe
malaria, and consequently only 45 ICUs participated in the study.
Some data were missing from the database. Nevertheless, this
point was carefully taken into account and corrected by the
statistical methodology using both multiple imputation and
bootstrapping [14].
Our findings suggest several targets for improving the
management of severe imported malaria. First, inappropriate
chemoprophylaxis was common among both survivors and
nonsurvivors. Efforts to improve adherence to chemoprophylaxis
regimens are clearly needed. Second, we identified several
independent predictors of death. A more standardized and
aggressive treatment approach to patients with these predictors
(and in particular immediately upon the onset of neurological
impairment) might decrease the mortality rate. Third, we used
quinine in nearly all our patients. A large study of adults with
severe malaria conducted recently in Asia found that artesunate
was associated with lower mortality rates and better tolerance,
compared to quinine [8]. Thus, it can be hoped that the
introduction of intravenous artesunate in nonendemic areas will
improve survival rates in patients with severe imported malaria
[25]. Unfortunately, intravenous artesunate is not yet available in
France or other European countries. The only data on artesunate
therapy for severe imported falciparum malaria come from a letter
about 9 Norwegian patients, all of whom achieved a full recovery
[26], and from the 2008 report of the Centers for Disease Control
on 24 patients, of whom 1 died [2]. According to all these data, we
wish to have parenteral artesunate, produced according to good
manufacturing practices, in Europe.
In conclusion, severe imported falciparum malaria in adults still
carried a high mortality rate in patients who received quinine and
optimal supportive care in the ICU. The strongest predictors of
death at ICU admission were older age, neurological impairment,
and high parasitemia. Patients with these factors may require the
highest level of treatment intensity. The results of our multicenter
study are probably relevant to other nonendemic countries where
high-quality healthcare is available.
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